Holen Sie sich die Stockscreener-App
7.00
2.80%
-0.15
Quoin Pharmaceuticals Ltd Adr Aktie (QNRX) Neueste Nachrichten
Tuesday’s insider buys and sells: Quoin Pharma executives lead purchases - Investing.com
Quoin Pharmaceuticals COO Denise Carter buys $99,991 in ADSs - Investing.com
Quoin Pharmaceuticals director Culverwell buys $29,992 in ADSs - Investing.com
Quoin Pharmaceuticals CFO Lawlor buys $49,990 in company stock - Investing.com
Quoin Pharmaceuticals CEO Michael Myers buys $99,991 ADSs - Investing.com India
Dow Gains 100 Points; Chicago PMI Falls In August - Sahm
Quoin Pharmaceuticals Stock Surges Friday: What's Happening? - Sahm
Why Elastic Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals raises $30.8M in private placement - Investing.com
Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million - Barchart.com
Quoin Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Barchart.com
Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026 - Barchart.com
Cash flow from investing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Book value per share of Quoin Pharmaceuticals. Ltd Sponsored ADR – LS:A41BEM - TradingView
Average basic shares outstanding of Quoin Pharmaceuticals. Ltd Sponsored ADR – LSX:A41BEM - TradingView
Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops - Sahm
Price to earnings forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Price to book forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Enterprise value to EBIT forward of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome - Sahm
Form PRE 14A Quoin Pharmaceuticals Ltd. For: 6 July By Investing.com - Investing.com India
QNRXQuoin Pharmaceuticals Ltd ADR Volatility & Greeks - Finviz
Quoin Pharmaceuticals. Ltd Sponsored ADR Actuals & Estimates (NASDAQ:QNRX) - TradingView
Why Leifras Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome - Sahm
These stocks that are showing activity before the opening bell on Wednesday. - ChartMill
Trending Stocks Today | Quoin Pharmaceuticals Shoots up 41.6% Post-Market - Moomoo
Quoin Pharmaceuticals establishes Japan subsidiary for QRX003 - Investing.com
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program - Sahm
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome - Sahm
Quoin Pharmaceuticals stock rises on rare disease IND filing By Investing.com - Investing.com South Africa
Quoin Pharmaceuticals stock rises on rare disease IND filing - Investing.com
Number of shareholders of Quoin Pharmaceuticals. Ltd Sponsored ADR – FWB:2EB0 - TradingView
Quoin Pharmaceuticals (QNRX) Earnings Date and Reports 2026 - marketbeat.com
Quoin Pharmaceuticals initiated with a Buy at Lucid Capital - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026 - Sahm
Quoin Pharmaceuticals DRC News Today (QNRX) - Investing.com
Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin - TipRanks
Unusual VolumeStock ScreenerNews - Finviz
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs - Sahm
Quoin Pharmaceuticals price target raised to $35 from $25 at Alliance Global - TipRanks
Quoin Pharmaceuticals (NASDAQ: QNRX) advances NS drug but warns on cash - Stock Titan
Quoin Pharmaceuticals provides update following QRX003 Type C meeting with FDA - TipRanks
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026 - ChartMill
Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome - Sahm
Maxim Group Sticks to Its Buy Rating for Quoin Pharmaceuticals (QNRX) - The Globe and Mail
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail
Quoin Pharmaceuticals highlights continued growth of NETHERTON NOW program - TipRanks
Critical Contrast: Amneal Pharmaceuticals (NASDAQ:AMRX) versus Quoin Pharmaceuticals (NASDAQ:QNRX) - Defense World
Form 13G Quoin Pharmaceuticals For: 15 December - Investing.com
US Stock Market today: Nasdaq, S&P 500 open lower amid elevated tech valuation concerns, Dow Jones up 0.17% - Livemint
Why NioCorp Developments Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Quoin Pharmaceuticals stock soars after securing premium-priced funding - Investing.com
Why New Fortress Energy Shares Are Trading Higher By 41%; Here Are 20 Stocks Moving Premarket - Sahm
Quoin Pharmaceuticals Releases Fifth NETHERTON NOW Video Featuring Writers and Influencers Allie and Kaleigh Fasanella, Twin Sisters Living with Netherton Syndrome - ChartMill
Quoin Pharmaceuticals’ NETHERTON NOW Campaign Surpasses One Million Video Views, Amplifying Global Awareness of Netherton Syndrome - ChartMill
Quoin Pharmaceuticals (QNRX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Quoin Pharmaceuticals receives FDA rare pediatric disease designation for QRX003 - Investing.com
QNRX Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
0.63%
3.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):